Cite this article as: BMJ, doi:10.1136/bmj.38282.607859.AE (published 29 November 2004) United Kingdom back pain exercise and manipulation (UK BEAM) randomised trial: cost effectiveness of physical treatments for back pain in primary care UK BEAM Trial Team Full authorship details are given in the accompanying paper (doi: 10.1136/bmj.38282.669225.AE). Abstract
poorer outcomes than those randomised to the control groupand encouraged to keep active.5 A Swedish study found no
Objective To assess the cost effectiveness of adding spinal
differences in costs or outcomes between physiotherapy and chi-
manipulation, exercise classes, or manipulation followed by
ropractic manipulation.6 In contrast, a UK trial comparing
exercise (“combined treatment”) to “best care” in general
private chiropractic and NHS outpatient treatment found that
practice for patients consulting with low back pain.
reductions in time off work more than offset the net health serv-
Design Stochastic cost utility analysis alongside pragmatic
ice cost incurred by chiropractic.7 To reduce the uncertainty sur-
randomised trial with factorial design.
rounding the cost effectiveness of these physical treatments for
Setting 181 general practices and 63 community settings for
back pain, we report the economic evaluation of the UK BEAM
physical treatments around 14 centres across the United
Kingdom. Participants 1287 (96%) of 1334 trial participants. Main outcome measures Healthcare costs, quality adjusted life
years (QALYs), and cost per QALY over 12 months. Interventions Results Over one year, mean treatment costs relative to “best “Best care” in general practice (the “comparator” treatment)—We
care” were £195 ($360; €279; 95% credibility interval £85 to
trained practice teams in “active management” and provided The
£308) for manipulation, £140 (£3 to £278) for exercise, and
£125 (£21 to £228) for combined treatment. All three active
Exercise programme—This comprised an initial assessment and
treatments increased participants’ average QALYs compared
up to nine classes in community settings over 12 weeks.10
with best care alone. Each extra QALY that combined
Spinal manipulation package—The UK chiropractic, osteo-
treatment yielded relative to best care cost £3800; in economic
pathic, and physiotherapy professions agreed to use a package of
terms it had an “incremental cost effectiveness ratio” of £3800.
techniques developed by a multidisciplinary group, during eight
Manipulation alone had a ratio of £8700 relative to combined
treatment. If the NHS was prepared to pay at least £10 000 for
Combined treatment—Participants received six weeks of
each extra QALY (lower than previous recommendations in the
manipulation followed by six weeks of exercise. Treatments were
United Kingdom), manipulation alone would probably be the
otherwise those given to the manipulation only or exercise only
best strategy. If manipulation was not available, exercise would
have an incremental cost effectiveness ratio of £8300 relative tobest care. Study design Conclusions Spinal manipulation is a cost effective addition to
We randomised participants between these four interventions.
“best care” for back pain in general practice. Manipulation
We also randomised participants receiving manipulation
alone probably gives better value for money than manipulation
between private and NHS premises. Thus the study had a three
by two factorial design. As the accompanying clinical paper didnot find statistically significant differences in outcome between
Introduction
manipulation in NHS and private premises, this paper analysesthe simpler two by two factorial trial.
Back pain is a major economic problem. Before the accompany-ing clinical paper,1 little evidence existed for the effectiveness of
Data collection
two commonly used treatments—exercise classes and spinal
Participants completed questionnaires, including the EQ-5D
manipulation. Until the UK BEAM trial, little evidence existed
health status instrument,12 13 at baseline, three months, and 12
for the cost effectiveness of those treatments.2 3
months. Over the same period they recorded use of health
An economic evaluation in British primary care found that
care—including hospital stays, visits to secondary and primary
physiotherapy led exercise classes were less expensive and more
care, and physical therapists, both private and within the NHS—
effective than general practice care alone.4 In contrast, a Finnish
whether related to back pain or not. Physical therapists
study found that patients randomised to exercise, different from
completed record forms, including the number of treatments
that investigated by the British study, had higher costs and
BMJ Online First bmj.com
So we estimated the mean costs of, and mean QALYs gained
Table 1 Reported cost of units of healthcare resource
by, each of four distinct treatments. As most trials compare just
Healthcare resource Cost per unit (£)
two treatments, we adopted a more general approach. Firstly, we
ranked treatments by mean cost, starting from the least costly.
Secondly, we calculated incremental cost effectiveness ratios for
all treatments by dividing incremental costs by incremental
QALYs. Finally, we excluded from the comparison “dominated”
Class (assuming mean of 10 participants per class)6
treatments and treatments subject to “extended dominance,”20
and we recalculated ratios if necessary. A treatment is dominated
if it generates worse health outcomes and costs more than an
alternative treatment. Extended dominance occurs when a treat-
ment is less effective and has a higher incremental cost effective-
ness ratio than an alternative treatment.20
Trial participants registered with the same general practice
formed clusters within centres, and centres formed clusters
within the trial. In these circumstances, the use of standard cost
utility methods may yield misleading results.21 Hence we used
Bayesian Markov Chain Monte Carlo methods within the statis-
tical package MLwiN to undertake bivariate multilevel analysis.22
Because evidence about the cost effectiveness of physical
treatments for back pain is weak, we started by giving each of the
four treatments “uninformative” prior probabilities. In other
words, we made no assumptions about the probabilities beforeUK BEAM that one treatment was more effective or cost more
Unit costs
To contribute to health policy for an expensive condition, we
To report the uncertainty due to sampling variation, we
conducted an economic analysis from the perspective of health
calculated Bayesian credibility intervals (Bayesian analogue of
care. Participants’ follow up periods lay between August 1999
95% confidence intervals) and plotted cost effectiveness accept-
and April 2002. We therefore used unit costs in pounds sterling
ability curves.23 24 As UK BEAM compared four rather than two
at 2000-1 prices to value the resources they used (table 1). We did
treatments, we plotted multi-treatment cost effectiveness accept-
not adjust or discount the costs, as we focused on effects over
ability curves. These curves show the posterior (after UK BEAM)
only one year. We costed NHS care from national averages for
probability that each strategy is better than the other three across
England.14 15 We costed private care by using information from a
the range of values that decision makers may pay to achieve an
major insurance provider.16 As the accompanying paper found
additional QALY. This assumes that these people have
no difference in clinical outcome between manipulation in
maximum values that they are willing to pay for an additional
private and NHS premises,1 our main economic analysis used
QALY. It is this “ceiling” against which they should compare esti-
costs for the less expensive NHS premises. Nevertheless, we
mated incremental cost effectiveness ratios and read the
explored this assumption in a sensitivity analysis.
probability that the corresponding treatment is “best.” This deci-
Health outcomes
sion oriented formulation selects as “best” or “cost effective” that
The EQ-5D measures health on five three point scales—mobility,
treatment, with an incremental cost effectiveness ratio below the
self care, usual activities, pain-discomfort, and anxiety-
ceiling, likely to be more effective than competing treatments.
depression—thus putting participants into one of 243 ( = 35)
This is not necessarily the strategy with the lowest ratio, as that
health states.12 A large British sample valued these states on a
may generate fewer QALYs.23 To cover scenarios in which either
“utility” scale on which being dead scores zero and perfect health
exercise or manipulation is not available, we also plotted
scores one.13 We estimated how many quality adjusted life years
two-treatment cost effectiveness acceptability curves to compare
(QALYs) participants had experienced over their year in the UK
best care with manipulation alone or exercise alone.
BEAM trial by calculating “areas under (health utility) curves.”17
Finally, we did three sensitivity analyses to explore how
For example, if they reported that their utility averaged 0.5, we
dependent the results were on participants’ estimates of total
calculated that they had experienced half a QALY over the year
costs and our estimates of unit costs. The first analysis examined
in UK BEAM. To avoid bias we adjusted for differences in base-
the influence of cost “outliers,” very large healthcare costs
reported by a few participants. We excluded those participants
Cost utility analysis
whose costs exceeded £2000 ($3700; €2900) (more than eight
Because the accompanying clinical paper found statistically
times the median cost) in case their chance allocation between
significant interactions between manipulation and exercise,1 it
compares four distinct treatments within the factorial design.19
The other two sensitivity analyses assessed the influence of
Although costs show no interaction between treatments, this
the unit costs of manipulation. One did so by costing the
paper also compares these four treatments for three reasons.
scenario in which the NHS buys all manipulation from the
Firstly, as costs vary much more than clinical outcomes, this is
private sector using private manipulation costs. The other did so
prudent. Secondly, those people responsible for allocating
by costing the scenario in which the NHS buys half its manipula-
resources need to choose between these four treatments. Finally,
tion from the private sector, using private costs when trial
this epitomises the Bayesian statistical approach adopted in this
manipulation took place in private premises and NHS costs
BMJ Online First bmj.com Table 2 Reported mean (SD) cost (£) of health care over 12 months by treatment group Best care in general practice Best care plus exercise alone Best care plus manipulation alone Best care plus manipulation and Healthcare resource exercise (n=322)
*Including spinal manipulation or exercise class outside UK BEAM.
a mean of 0.041 (95% credibility interval 0.016 to 0.066) QALYsper participant, combined treatment generated 0.033 ( − 0.001 to
Recruitment
0.067), and exercise generated 0.017 ( − 0.017 to 0.051).
We recruited 1334 participants from 181 practices around 14centres across the United Kingdom. Of these, 1287 (96.5%)
Cost utility analysis
yielded enough data for inclusion in the economic analysis; 326
When manipulation and exercise are both available, combined
received best care in general practice, 297 received best care plus
treatment generates 0.033 more QALYs than does best care at
exercise, 342 received best care plus manipulation, and 322
an additional cost of £125, yielding an incremental cost effective-
received best care plus combined treatment.
ness ratio of £3800 (table 4). This achievement dominates that of
Clinical outcomes
exercise alone, which costs more and achieves less over 12
The accompanying clinical paper reports that exercise achieved
months. Manipulation alone, however, can generate 0.008 more
a small functional benefit at three months but not at one year;
QALYs than combined treatment for an extra £70, yielding a
manipulation achieved a small to moderate benefit at three
ratio of £8700 relative to combined treatment. If exercise is not
months and a small benefit at one year; and combined treatment
available, however, manipulation generates 0.041 more QALYs
achieved a moderate benefit at three months and a small benefit
than best care, yielding an incremental cost effectiveness ratio of
at one year (all statistically significant).1 These benefits were spe-
£4800. If manipulation is not available, exercise generates 0.017
cific to back pain, in contrast to the general health benefits deter-
more QALYs than best care, yielding a ratio of £8300.
The cost effectiveness acceptability curves in the top panel of
the figure show the probability that each of the four treatments is
better than the other three when all are available. If the ceiling
Combined treatment had the highest therapy costs but the low-
was only £2000 per QALY, the top panel shows 74% probability
est subsequent hospital costs (table 2). So it cost only £125 (95%
that best care would be the best strategy. If the ceiling was £5000
credibility interval £21 to £228) more than best care, whereas
per QALY, combined treatment has a lower incremental cost
exercise cost £140 (£3 to £278) more than best care, and
effectiveness ratio than this; the top panel of the figure shows a
manipulation cost £195 (£85 to £308) more.
46% chance that it would be best. If the ceiling was £15 000 per
Health outcomes
QALY (lower than implied by previous recommendations by the
Physical interventions improved EQ-5D scores more than did
National Institute for Clinical Excellence25), manipulation alone
best care (table 3). Relative to best care, manipulation generated
has a lower incremental cost effectiveness ratio than this; the top
Table 3 Utilities and QALYs over 12 months by treatment group Best care in general Best care plus exercise Best care plus manipulation Best care plus manipulation practice (n=326) alone (n=297) alone (n=342) and exercise (n=322)
Difference (95% credibility interval) in mean QALYs
relative to best care in general practice*
QALY=quality adjusted life year. *Estimated by analysis of covariance with adjustment for baseline EQ-5D score and then rounded to three significant figures. BMJ Online First bmj.com Table 4 Cost utility analysis by scenario and treatment group* Incremental cost Mean cost* Mean adjusted effectiveness ratio to Treatment group QALYs*† nearest £100 or comment Manipulation and exercise both available (n=1287) Exercise not available (n=623) Manipulation not available (n=668)
*Markov Chain Monte Carlo estimates from bivariate multilevel model. †Estimated by analysis of covariance with adjustment for baseline EQ-5D score and then
rounded to three significant figures.
panel shows a 50% probability that it would be best. The costeffectiveness acceptability curve in the middle panel of the figure
shows the probability that manipulation is better than best care
when exercise is not available; and vice versa for the curve in thebottom panel. Sensitivity analyses
To assess the robustness of these results to the presence of “out-
liers,” we excluded the 51 participants (9, 16, 16, and 10 from best
care, exercise alone, manipulation alone, and combined
treatment respectively) whose healthcare costs exceeded £2000. Manipulation achieves extended dominance over both exercise
and combined treatment (table 5). It is thus the only alternativeto best care, with an incremental cost effectiveness ratio of £3000
per additional QALY. At a ceiling of £10 000 per QALY,
Cost effectiveness acceptability curves. Top: manipulation and exercise available;
manipulation has a 73% chance of being best. If manipulation
middle: exercise not available; bottom: manipulation not available.
alone were not available, exercise would have a ratio of £4100.
ICER=incremental cost effectiveness ratio
The second sensitivity analysis used private costs for manipu-
lation that took place in private premises. Combined treatment
Strengths and weaknesses of the study
now achieves extended dominance over exercise, with an
Although two of our three sensitivity analyses—those that used
incremental cost effectiveness ratio of £6600 compared with best
larger unit costs in whole or in part—changed these critical
care (table 5). Manipulation alone then has a ratio of £8700 rela-
thresholds a little, they did not alter the essentials of these
conclusions. The other sensitivity analysis, which removed 51
The third sensitivity analysis used private unit costs for all
“outliers” from the UK BEAM dataset, was more favourable to
manipulation within the trial. The findings are analogous to
manipulation than was the primary analysis. Under this scenario
those in the second scenario. Exercise is subject to extended
manipulation cost only £3000 per QALY relative to best care in
dominance, and combined treatment has an incremental cost
effectiveness ratio of £8600 compared with best care (table 5).
We believe that this is the first study of physical therapy for
Manipulation alone then has a ratio of £10 600 relative to com-
low back pain to show convincingly that both manipulation
alone and manipulation followed by exercise provide cost effec-tive additions to care in general practice. Indeed, as we trained
Discussion
practice teams in the best care of back pain, we may have under-estimated the benefit of physical therapy when compared with
Principal findings
“usual care” in general practice. The detailed clinical outcomes
This economic evaluation supports and extends the findings of
reported in the accompanying paper reinforce these findings by
the clinical evaluation of the UK BEAM trial reported in the
showing that the improvements in health status reported here
accompanying paper.1 If decision makers value additional quality
reflect statistically significant improvements in function, pain,
adjusted life years (QALYs) at much less than £3800, “best care”
disability, physical and mental aspects of quality of life, and
in general practice is probably the best strategy. If their valuation
lies between £3800 and £8700, spinal manipulation followed byexercise classes (“combined treatment”) is likely to be the best
Unanswered questions
treatment. If their valuation is well above £8700, manipulation
Funding constraints prevented us from following up participants
alone is probably the best treatment.
for more than 12 months. Given that they continued to show
BMJ Online First bmj.com Table 5 Sensitivity analyses by treatment group* What is already known on this topic Incremental cost Mean cost* Mean adjusted effectiveness ratio to Treatment group QALYs*† nearest £100 or comment Excluding participants with health care costing more than £2000 over 12 months (n=1266)
Little evidence exists for the effectiveness and cost
effectiveness of two commonly used treatments—exercise
Subject to extendeddominance by manipulation
What this study adds
Spinal manipulation, exercise classes, and manipulation
followed by exercise all increased participants’ quality of life
NHS provides manipulation for only 50% of patients (n=1287)
over 12 months by more than did “best care” in general
Adding spinal manipulation to best care in general practice
is effective and cost effective for patients in the United
If the NHS can afford at least £10 000 for each quality
adjusted life year yielded by physical treatments,
Manipulation provided only in private premises (n=1287)
manipulation alone probably gives better value for money
Subject to extendeddominance by manipulationand exercise
Meaning of the study
Adding spinal manipulation to best care in general practice is
effective and cost effective for patients with back pain in the
£10 600 relative tomanipulation and exercise
United Kingdom. If the NHS can afford more than £10 000 foran extra QALY, manipulation alone probably gives better value
QALY=quality adjusted life year. *Markov Chain Monte Carlo estimates from bivariate hierarchical multilevel model.
for money than manipulation followed by exercise. These
†Estimated by analysis of covariance with adjustment for baseline EQ-5D score and then
conclusions hold even if the NHS has to buy spinal manipulation
rounded to three significant figures.
We thank all participants—patients, primary care staff, and collaborators
benefits of treatment at 12 months, the cost effectiveness of both
listed in the accompanying clinical paper—for their contributions. We thank
manipulation and combined treatment may be better than we
Mark Sculpher and Daphne Russell for advice on analysis. Members of the
UK BEAM Trial Team: Ian Russell, Martin Underwood, Stephen Brealey,Kim Burton, Simon Coulton, Amanda Farrin, Andrew Garratt, Emma Har-
Commissioning decisions should depend on local circum-
vey, Louise Letley, Andrea Manca, Jeannett Martin, Jennifer Klaber Moffett,
stances, notably the availability of spinal manipulation and exer-
Veronica Morton, David Torgerson, Madge Vickers, Ken Whyte, Melanie
cise physiotherapists. Although combined therapy is an attractive
option, this depends on an ample supply of both trained
Contributors: See accompanying clinical paper.
manipulators prepared to work for the NHS and exercise physi-
Funding: Medical Research Council (research costs); NHS in England,
otherapists with access to suitable premises. As back pain is a
Northern Ireland, Scotland, and Wales (excess treatment and servicesupport costs).
common problem, making manipulation generally available will
Competing interests: LL, JM, MU, MV, and KW have received salaries from
require many therapists. In the United Kingdom there are 2100
the MRC. MU has received fees for speaking from Menarini Pharmaceuti-
registered chiropractors, 3200 registered osteopaths, and about
cals, the manufacturers of dexketoprofen and ketoprofen, and Pfizer, the
5000 manipulative physiotherapists (Ann Thomson, Chair of
manufacturers of celecoxib and valdecoxib. The other 12 authors have
British Association of Chartered Physiotherapists in Manipula-
tion, on behalf of the Chartered Society of Physiotherapy,
Ethical approval: The Northern and Yorkshire multicentre research ethicscommittee and 41 local research ethics committees approved the trial pro-
personal communication, 2003). According to the unit costs we
used in our analysis, they can achieve higher incomes in privatepractice than in the NHS. In the short term it may be difficult to
UK BEAM Trial Team. United Kingdom back pain exercise and manipulation (UK
make manipulative or combined treatment generally available
BEAM) randomised trial: effectiveness of physical treatments for back pain in primarycare. BMJ 2004;329:doi = 10.1136/bmj.38282.669225.AE.
Baldwin ML, Côté P, Frank JW, Johnson WG. Cost-effectiveness studies of medical and
Whereas physiotherapists can rapidly train to deliver the
chiropractic care for occupational low back pain: a critical review of the literature. SpineJ 2001;1:138-47.
exercise package, insufficient trained manipulators are available
Maetzel A, Li L. The economic burden of low back pain: a review of studies published
in the United Kingdom to meet potential demand, and it will
between 1996 and 2001. Best Pract Res Clin Rheumatol 2002;16:23-30.
take several years to produce additional manipulators. Indeed, if
Klaber Moffett J, Torgerson D, Bell-Syer S, Jackson D, Llewlyn-Phillips H, Farrin A, et al. Randomised controlled trial of exercise for low back pain: clinical outcomes, costs, and
this needs new training programmes, it may be decades before
preferences. BMJ 1999;319:279-83.
the NHS can implement these findings. Fortunately, using
Malmivaara A, Hakkinen U, Heinrichs M, Koskenniemi L, Kuosma E, Lappi S, et al. Thetreatment of acute low back pain—bed rest, exercises, or ordinary activity? N Engl J Med
private costs for manipulation had little effect on the choice of
best treatment. Purchasing manipulation from the private sector
Skargren EI, Carlsson PG, Oberg BE. One-year follow-up comparison of the cost andeffectiveness of chiropractic and physiotherapy as primary management for back pain.
to provide treatment within the NHS would still represent good
value for money if decision makers were willing to pay £10 000
Meade TW, Dyer S, Browne W, Townsend J, Frank AO. Low back pain of mechanicalorigin: randomised comparison of chiropractic and hospital outpatient treatment. BMJBMJ Online First bmj.com
Underwood M, O’Meara S, Harvey E, UK BEAM Trial Team. The acceptability to pri-
21 Manca A, Rice N, Sculpher MJ, Briggs AH. Assessing generalisability by location in
mary care staff of a multidisciplinary training package on acute back pain guidelines.
trial-based cost-effectiveness analysis: the use of multilevel models. Health Econ 2004
Jun 14 [Epublication ahead of print].
Roland M, Waddell G, Klaber Moffett J, Burton AK, Main CJ, Cantrell T. The back book.
22 Rasbash J, Browne W, Goldstein H. A user’s guide to MLwiN Version 2.1. London: Insti-
tute of Education, University of London, 2000.
10 Klaber Moffett J, Frost H, UK BEAM Trial Team. Back to fitness programme: the
23 Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of
manual for physiotherapists to set up the classes. Physiotherapy 2000;85:295-305.
cost-effectiveness acceptability curves. Health Econ 2001;10:779-87.
11 Harvey E, Burton AK, Moffett JK, Breen A, UK BEAM Trial Team. Spinal manipulation
24 Fenwick E, O’Brien BJ, Briggs AH. Cost-effectiveness acceptability curves—facts,
for low-back pain: a treatment package agreed to by the UK chiropractic, osteopathy
fallacies and frequently asked questions. Health Econ 2004;13:405-15.
25 Raftery J. NICE: faster access to modern treatments? Analysis of guidance on health
and physiotherapy professional associations. Man Ther 2003;8:46-51.
technologies. BMJ 2001;323:1300-3.
12 Kind P. The EuroQoL instrument: an index of health-related quality of life. In: Spilker
B, ed. Quality of life and pharmacoeconomics in clinical trials. Philadelphia:
13 Kind P, Hardman G, Macran S. UK population norms for EQ-5D. York: Centre for Health
Correspondence to: Andrea Manca, research fellow, Centre for Health Economics,
Economics, University of York, 1999. (Discussion paper 172.)
University of York, York YO10 5DD am126@york.ac.uk
14 Chartered Institute of Public Finance and Accountancy. The health service database 2002.
15 Netten A, Dennett J, Knight J. Unit costs of health and social care. Canterbury: Personal
Social Services Research Unit, University of Kent, 2002.
16 BUPA Hospitals UK. How much will it cost? www.bupahospitals.co.uk/asp/paying/
Amendment
priceguides.asp (accessed 17 Nov 2004).
17 Matthews JNS, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements
This is Version 2 of the paper. In this version, the text relating
in medical research. BMJ 1990;300:230-5.
to the figure has been amended to state that the curve in the
18 Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based
cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ
middle panel shows the probability that manipulation is
2004 Oct 20 [Epublication ahead of print].
better than best care when exercise is not available, and vice
19 McAlister FA, Straus SE, Sackett DL, Altman DG. Analysis and reporting of factorial
versa for the curve in the bottom panel [these were
trials: a systematic review. JAMA 2003;289:2545-53.
incorrectly given the other way round in the previous
20 Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine.
New York: Oxford University Press, 1996. BMJ Online First bmj.com
CEYLON COLLEGE OF PHYSICIANS MEDICINE UPDATE Vol. 18 No. 1 Compiled by Dr. Henry N. Rajaratnam MD FCCP FRCP (London) (Hon) FRACP (Hon) FSLCGP FACE 1:1 What’s new in TB?. a) Multi drug resistant TB – defined as resistance to at least Rifampicin and INAH are on the increase and considered incurable with conventional regimes. b) HIV increases multi drug resistance, a
Substance Abuse Treatment Breaking News for the T reatment Field Acamprosate: A New Medication for Alcohol Use Disorders What is acamprosate? glutamate and gamma-aminobutyric acid (GABA) neurotransmitter systems. Although acamprosate’s Acamprosate (calcium acetyl homotaurinate) is a mechanism of action has not been clearly established, new prescription medication t